Is Aphria’s (TSX:APHA) Stock Ready to Soar?

Now that all the drama is in the rear-view mirror, is it the right time to buy Aphria Inc (TSX:APHA) (NYSE:APHA)?

Aphria Inc (TSX:APHA)(NYSE:APHA) has seen its share of drama over the past year. However, the pot company’s latest financial results were a breath of fresh air. Aphria finally put all its troubles behind and seems to be firing on all cylinders.

Could this be the start of a rally for the Ontario-based pot grower? Let’s look at what Aphria did during its fourth quarter. 

Revenues continue to soar

Aphria’s third-quarter financial results were somewhat disappointing, partly because of a lack of organic growth. The bulk of the firm’s top line increase was as a result of several international acquisitions.

Aphria’s core domestic operations were not impressive, but this may not be as big a problem as it seems.

It isn’t a secret that the Canadian pot market is highly competitive and risks suffering from a supply glut. Perhaps Aphria can keep its earnings afloat by relying on its international operations. 

During the fourth quarter, Aphria posted a net revenue of $128.6 million, which represents a sequential quarterly increase of 75% and a whopping 969% year-over-year jump.

Its average retail selling price for medical cannabis decreased by 4% sequentially, while its average retail selling price for recreational cannabis increased by 11%.

Once again, however, the lion’s share of the company’s net revenue was as a result of international acquisitions. Distribution revenue (which includes revenue from Aphria’s German-based subsidiary CC Pharma) accounted for almost $100 million (about 78%) of net revenue. Sales of cannabis produced were $33 million. 

Aphria delivers a profit

Aphria had to incur a one-time impairment charge related to the much discussed and much- criticized LATAM acquisitions. This charge cost the company $50 million in non-cash expenses, dragging the firm’s earnings down in the third quarter. The fourth quarter shows a very different picture.

To everyone’s surprise, Aphria managed to deliver a net profit of $15.760 million, or about $0.05 per share, which is a major improvement, both sequentially and compared to the corresponding period of the previous fiscal year. Most analysts expected Aphria to post a net loss in the neighbourhood of $0.05 per share.

For fiscal year 2020, Aphria expects to post revenues between $650 million and $700 million, which would represent an increase of about 174%-195% from fiscal year 2019.

The company also expects its earnings before taxes, expenses, depreciation and amortization (EBITDA) to be between $88 million and $95 million. 

Finally out of the shadows 

It looks like Aphria finally put all its demons aside and manage to deliver stellar financial results. Naturally, the firm was rewarded: its share price jumped by as much as 40% after its earnings report was released.

It might be worth considering purchasing shares of Aphria before they skyrocket.

Fool contributor Prosper Bakiny has no position in any of the stocks mentioned.  

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »